Policy Analysis - OHE

Office of Health Economics

Leading intellectual authority on global health economics

Search publications, topics, authors and more

Newsletter SignupSubscribe

News & Insights

News
Events
Insights
Bulletin

News
Events
Insights
Bulletin

News & Insights

News
Events
Insights
Bulletin

Newsletter SignupSubscribe

News
Events
Insights
Bulletin

Search publications, topics, authors and more

Research & Publications
News & Insights
Education
Innovation Policy Prize

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:

Antimicrobial Resistance (AMR)
Biosimilars
Cell and Gene Therapies
Chronic Diseases
Combination Therapies
COVID-19 Research
Digital Health
Drug Development/R&D
Emerging Markets
EQ-5D and PROMs
Indication-Based Pricing
Health Care Systems
Health Data and Statistics
Health Technology Assessment
Precision Medicine
Prevention
Real-World Evidence
Sustainability
Use of Medicines
Value-Based Pricing
Vaccine Research

Economics of Innovation
Measuring and Valuing Outcomes
Policy, Organisation and Incentives in Health Systems
Value, Affordability and Decision Making

News & Insights

News
Events
Insights
Bulletin

Education

Education Hub
OHE Graduate School
EVIA Programme

Innovation Policy Prize

The Prize Fund
2024 Prize Fund
2022 Prize Fund

Search publications, topics, authors and more

Latest Research & Publications

Antimicrobial Resistance (AMR)
Value, Affordability, and…
Generics

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Health Data and Statistics
Economics of Innovation

Data Governance Arrangements for Real-World Evidence in Japan

Policy, Organisation and…
Injury and Trauma

Unrelieved Pain in Palliative Care in England

Health Technology Assessment…
Economics of Innovation
Determining Value

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

EQ-5D and PROMs
Measuring and Valuing Outcomes
Clinical Outcomes

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

Value-Based Pricing
Economics of Innovation
Health Policy and Regulation

Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?

Indication-Based Pricing
Economics of Innovation
Health Policy and Regulation

Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?

Health Technology Assessment…
Economics of Innovation
Cancer

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a central role for HTA and value assessment

All Publications

Filter by:

Antimicrobial Resistance (AMR)

Biosimilars

Cell and Gene Therapies

Chronic Diseases

Combination Therapies

COVID-19 Research

Digital Health

Drug Development/R&D

Emerging Markets

EQ-5D and PROMs

Indication-Based Pricing

Health Care Systems

Health Data and Statistics

Health Technology Assessment

Precision Medicine

Prevention

Real-World Evidence

Sustainability

Use of Medicines

Value-Based Pricing

Vaccine Research

Economics of Innovation

Measuring and Valuing Outcomes

Policy, Organisation and Incentives in Health Systems

Value, Affordability and Decision Making
News

Events

Insights

Bulletin
Education Hub

OHE Graduate School

EVIA Programme
The Prize Fund

2024 Prize Fund

2022 Prize Fund

Events
About Us
OHE Experts
Join OHE
Contact Us

Newsletter SignupSubscribe

Filter results by

Theme

Select the product option you would like to filter Theme

Economics of Innovation Measuring and Valuing Outcomes Policy, Organisation and Incentives in Health Systems Value, Affordability, and Decision Making

Topic

Select the product option you would like to filter Topic

Antimicrobial Resistance (AMR) Biosimilars Cell and Gene Therapies Chronic Diseases Combination Therapies COVID-19 Research Dementia Digital Health Drug Development/R&D Emerging Markets EQ-5D and PROMs Health Care Systems Health Data and Statistics Health Technology Assessment (HTA) Indication-Based Pricing Innovation Policy Prize OHE Consulting Precision Medicine Prevention Real World Evidence (RWE) Research Sustainability Use of Medicines Vaccines Value-Based Pricing

Tag

Select the product option you would like to filter Tag

Adult Immunisation Alzheimer's Broader value and societal perspective in HTA Budget Impact Analysis Cancer Cardiovascular Disorders Care-givers Caring burden Cervical Cancer Clinical Outcomes Commentary Competition Dermatology Determining Value Diversity of Supply Drug Shortages Economic Evaluation Egypt Epidemiology and Public Health Epilepsy Gene therapies Generics Greece Haemophilia Health Policy and Regulation Health System Resiliency Healthcare Delivery Healthcare Expenditure Healthcare Funding Healthcare System Pressure (HCSP) India Infectious Diseases Inflation Reduction Act Injury and Trauma Innovation Israel Market Access Mental Health Pharmaceutical Industry Plant-based Policy Analysis Pricing and Reimbursement Primary Care Quality of Care Quality of Life Rare and Orphan Diseases Research Funding Resource Allocation Respiratory Cost Calculator Saudi Arabia Slovak Republic Societal preferences Supply of Medicine Türkiye Unmet Need Vaccines Value based pricing Webinar

Date 1

Select the product option you would like to filter Date

Date From

Month From

Year From

Date To

Month To

Year To

Author

Select the product option you would like to filter Author

Search authors

Rosanna Tarricone Edwine Barasa Angela Kairu Neil Mcauslane Adam Raymakers Kiran Bhatti Kelsey Moore Meindert Boysen Pedro Pita Barros Andrew Briggs

Content Type

Select the product option you would like to filter Content Type

news story insight events podcast bulletin publications

Insight
October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Insight
October 2022

The Economics of Antibiotics – Part 2: Value Assessment within the NICE-NHS AMR Pilot

Insight
October 2022

The Economics of Antibiotics – Part 1: Why NICE and NHS England are Testing an Innovative HTA and Payment Model to Tackle Antimicrobial Resistance

In a bull voice. A yellow background with a woman’s hand in fr

Bulletin
October 2022

The power of communication is health economics

Past Event
Annual Lecture
October 2022

OHE Annual Lecture 2022 | Universal Health Coverage: More Than Just Old Wine in a New Bottle?

Past Event
Sponsored Webinar
September 2022

Can we “Netflix” the Broken Antibiotics Market?

September-Bulletin_Adobe_sewcream-scaled-1

Bulletin
September 2022

An alphabet of priorities for the new Health Secretary

Bottles of sunscreen cream on blue background

Bulletin
August 2022

Balancing access, innovation and sustainability

HealthData&Stats_AdobeStock_168196575_landscape

Insight
August 2022

Improving the Measurement of Valued Output in Primary Care in England

News
July 2022

OHE is Leading Research to Develop an EQ-5D ‘Bolt-on’ for Hearing

Insight
July 2022

Reforming Primary Health Care in Middle-Income Countries: The Good, the Bad, and the Ugly

Lots of little business people working together with the puzzle

Bulletin
July 2022

Special Edition: OHE Masterclass Series

Insight
June 2022

The Benefits of Early Engagement with Payers and Patient Representatives: The Case Study of a MoCA Pilot Project on ANCA-associated Vasculitis

Insight
June 2022

The State of Play for Cost-effectiveness Thresholds

US-Drug-Pricing_Adobe_Снежана-Кудрявцева-scaled-1

Insight
June 2022

Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office

Past Event
Masterclass
June 2022

Collaborating on Payment Models to Unlock the Potential of Multi-Indication Therapies.

Leading intellectual authority on global health economics

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Cookies Policy

An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Twitter

Facebook

Copy

Share on Mastodon

Enter your Mastodon instance URL (optional)

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

Enable or Disable Cookies Enabled Disabled

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Enable or Disable Cookies Enabled Disabled

Please enable Strictly Necessary Cookies first so that we can save your preferences!

Notifications